Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
Optimizing limited antibody panels for efficient hematological disorders diagnosis by flow cytometry in resource-constrained setting.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yousafzai Yasar, Mir Awal, Hameed Mehreen, Khan Sadiq Noor, Mushtaq Hina, Islam Mujahid
Аннотация
OBJECTIVE: Flow cytometry (FC) is an expensive method that is unaffordable for many patients from underprivileged nations. We aimed to reduce the total budget of the test by optimizing a limited antibody panel, guided by morphological assessment.
MATERIALS AND METHODS: This retrospective observational study included 395 patients referred for flow cytometry at the Rehman Medical Institute in Peshawar. Bone marrow or peripheral blood samples were immunophenotyped using a limited panel of flow markers after morphological and cytochemical assessments. The samples were stained with fluorochrome-labeled monoclonal antibodies and analyzed using a Cytoflex flow cytometer. Data were analyzed using R and R studio by calculating frequency and percentage for descriptive statistics while results are presented in graphs, tables, and charts.
RESULTS: Out of 395 cases, an acute leukemia panel was requested for 225 (56.9%) cases, a lymphoproliferative panel for 80 (20.3%) cases, an absolute CD4 count for 80 (20.3%) cases, and proximal nocturnal hemoglobinuria (PNH) clone screening for 10 (2.5%) cases. Of the 225 acute leukemia cases, 160 (71.1%) were newly diagnosed and 65 (28.9%) were follow-up cases. In the follow-up cases, 21 (32.3%) were in remission, 13 (19.3%) were not in remission, and 31 (48.4%) were in relapse. 98% of cases of acute leukemia and lymphoproliferative disorders and 100% of cases of PNH and absolute CD4 count were conclusively diagnosed using our limited flow panels. Our panel achieved 74-82% average cost reductions and 61-68% reductions in turnaround time (TAT) compared with established reference laboratories in Pakistan.
CONCLUSIONS: Optimizing a minimal antibody panel in resource-limited settings enhances flow cytometry-based diagnosis, reduces patient financial burden, enables timely and accurate results, and guides treatment decisions to improve patient outcomes.
MATERIALS AND METHODS: This retrospective observational study included 395 patients referred for flow cytometry at the Rehman Medical Institute in Peshawar. Bone marrow or peripheral blood samples were immunophenotyped using a limited panel of flow markers after morphological and cytochemical assessments. The samples were stained with fluorochrome-labeled monoclonal antibodies and analyzed using a Cytoflex flow cytometer. Data were analyzed using R and R studio by calculating frequency and percentage for descriptive statistics while results are presented in graphs, tables, and charts.
RESULTS: Out of 395 cases, an acute leukemia panel was requested for 225 (56.9%) cases, a lymphoproliferative panel for 80 (20.3%) cases, an absolute CD4 count for 80 (20.3%) cases, and proximal nocturnal hemoglobinuria (PNH) clone screening for 10 (2.5%) cases. Of the 225 acute leukemia cases, 160 (71.1%) were newly diagnosed and 65 (28.9%) were follow-up cases. In the follow-up cases, 21 (32.3%) were in remission, 13 (19.3%) were not in remission, and 31 (48.4%) were in relapse. 98% of cases of acute leukemia and lymphoproliferative disorders and 100% of cases of PNH and absolute CD4 count were conclusively diagnosed using our limited flow panels. Our panel achieved 74-82% average cost reductions and 61-68% reductions in turnaround time (TAT) compared with established reference laboratories in Pakistan.
CONCLUSIONS: Optimizing a minimal antibody panel in resource-limited settings enhances flow cytometry-based diagnosis, reduces patient financial burden, enables timely and accurate results, and guides treatment decisions to improve patient outcomes.